Your browser doesn't support javascript.
loading
HMGB1 facilitates hypoxia-induced vWF upregulation through TLR2-MYD88-SP1 pathway.
Singh, Bandana; Biswas, Indranil; Bhagat, Saumya; Surya Kumari, Sarada; Khan, Gausal A.
Afiliação
  • Singh B; Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India.
  • Biswas I; Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India.
  • Bhagat S; Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India.
  • Surya Kumari S; Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India.
  • Khan GA; Department of Physiology, Defence Institute of Physiology and Allied Sciences, Lucknow Road, Timarpur, Delhi, India. gausalk@gmail.com.
Eur J Immunol ; 46(10): 2388-2400, 2016 10.
Article em En | MEDLINE | ID: mdl-27480067
ABSTRACT
Increased plasma level of von Willebrand Factor (vWF) is associated with major cardiovascular diseases. We previously reported that multimeric vWF binds to NO synthase and inhibits insulin-induced production of NO, thus promoting insulin resistance during acute hypoxia (AH). However, the transcriptional regulation of vWF during AH is not clearly understood. Here, we investigated the mechanisms underlying the upregulation of vwf in mice. AH significantly upregulates the tlr2, tlr3, myd88, and vwf expression and phosphorylation of specificity protein 1 (SP1). Furthermore, AH significantly upregulates high mobility group box-1 (HMGB1) in a time-dependent manner. Moreover, a TLR2 agonist upregulates vWF but a TLR3 agonist does not. Pretreatment with an HMGB1 inhibitor, TLR2-immunoneutralizing antibody, or SP1 inhibitor significantly inhibits vWF expression. Furthermore, Tlr2 silencing completely inhibited MYD88, vWF expression, and SP1 phosphorylation. However, pretreatment with glycyrrhizic acid or silencing of Tlr2 completely blocks binding of Sp1 to the Vwf promoter, thus inhibiting its expression, and enhances insulin resistance during AH. Patients with type 2 diabetes mellitus also showed significantly elevated levels of HMGB1, TLR2, SP1, and vWF, thereby supporting the results of the murine model of AH. Taken together, HMGB1 upregulates vWF in vivo through the TLR2-MYD88-SP1 pathway in mice.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator de von Willebrand / Proteína HMGB1 / Diabetes Mellitus Tipo 2 / Hipóxia Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator de von Willebrand / Proteína HMGB1 / Diabetes Mellitus Tipo 2 / Hipóxia Idioma: En Ano de publicação: 2016 Tipo de documento: Article